Daiichi Sankyo and AstraZeneca have reported positive interim data for datapotamab deruxtecan (Dato-DXd) to treat inoperable or metastatic hormone receptor (HR) positive, HER2 negative breast cancer, previously treated with endocrine-based therapy and systemic therapy.
The companies presented data from the TROPION-Breast01 (NCT05104866) trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid on 23 October.
Dato-DXd reduced the risk of disease progression or death by 37% compared to chemotherapy, but the results did not reach statistical significance at the time of cut-off.
The global, randomised, multicentre, open-label Phase III trial assessed the safety and efficacy of Dato-DXd, a specifically engineered TROP2-directed DXd antibody-drug conjugate (ADC). The dual primary endpoints are progression-free survival (PFS) as assessed by the blinded independent central review (BICR) and overall survival (OS). The study enrolled more than 700 patients globally.
AstraZeneca oncology R&D executive vice-president Susan Galbraith said: “With these TROPION-Breast01 results, datopotamab deruxtecan has the potential to meaningfully improve treatment expectations for patients with HR-positive, HER2-low or negative metastatic breast cancer.
“We look forward to continuing discussions with regulatory authorities with the goal of bringing this TROP2-directed antibody-drug conjugate to eligible patients as soon as possible.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Dato-DXd is currently in twelve clinical trials as part of the TROPION development programme, evaluating the drug across multiple tumours, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and hormone receptor-positive, HER2-low or negative breast cancer.
Positive data from the TROPION-Lung01 was reported in July for Dato-DXd to treat NSCLC, which showed a statistically significant improvement in PFS compared to the standard treatment, docetaxel.
According to GlobalData, Dato-DXd’s sales forecast is estimated to exceed $2.5bn by 2029. GlobalData predicts that AstraZeneca/Daiichi Sankyo’s datopotamab deruxtecan will lead the market. GlobalData is the parent company of Clinical Trials Arena.